Poster | Transient-Cyclic Structured Oligonucleotides
Explore the science behind AntiClastic™ cyclic oligonucleotide design. Download the poster Contact Us Poster Overview: This poster highlights a novel approach to antisense architecture using transient cyclic structures designed to improve potency, reduce immune activation, and enhance the overall drug-like properties of RNA therapeutics. Download the poster to see how cyclic design can help overcome […]
AI/ML in Antibody Discovery: What Works, What Doesn’t, What’s Next
Traditional antibody discovery is a war of attrition: screen thousands of candidates, fail late, and repeat. AI/ML changes that calculus by shifting failures from late and expensive to early and cheap. The result is fewer wet-lab cycles and a higher probability that the molecules you carry forward actually behave like drugs, while at the same time integrating learnings from failures at every stage.
From Data to Decisions in Antibody Discovery: Integrating AI/ML
WEBINAR Register for our upcoming webinar on integrating AI/ML workflows to drive smarter antibody selection, developability triage, and lead optimization. Tue, Mar. 31 | 11:00 AM EST Register Now Webinar Overview: AI/ML is reshaping antibody discovery, not by replacing the lab, but by making every wet-lab cycle smarter. In this webinar, Alloy will share practical, […]
Webinar: Unlocking Smarter Antibody Selection Strategies
Download our webinar on unlocking smarter antibody selection strategies to improve clinical success potential through integrated in vitro and in silico developability assessments. Watch now Webinar Overview: Many promising antibody therapeutics fail in development due to poor biophysical properties that can impact PK, stability, and manufacturability. This webinar presents an integrated strategy for early-stage developability […]
Overcoming challenging targets in antibody discovery
Webinar Overview: Unlock solutions for your most challenging targets with this webinar that demonstrates how Alloy Therapeutic’s precision approach to antibody discovery delivers results. This technical discussion explores: The power of hyperimmune mice: Benefit from ATX-GKH’s enhanced immune responses that produce higher serum titers and increased lymphoid cell output, especially valuable for high homology Streamline […]
Overcoming Antibody Discovery Challenges Against GPCR Targets
Generate high-quality therapeutic leads for GPCR targets in just 12 weeks with next-generation antibody discovery workflows The therapeutic promise of GPCR-targeted monoclonal antibodies G protein-coupled receptors (GPCRs) represent the largest family of cell surface receptors, serving as critical signaling nodes across all major physiological systems. These seven-transmembrane proteins control essential functions in metabolism, immunity, and […]
Poster | A Fully Integrated GPCR Antibody Discovery Workflow
Overcoming challenges in GPCRs with a fully integrated high-throughput antibody discovery workflow Download the poster Contact Us Poster Overview: Transform your approach to GPCR antibody discovery with this detailed poster that demonstrates how Alloy Therapeutics’ PerformAbTM yeast display platform and innovative technologies can overcome significant challenges in targeting these complex transmembrane proteins. Download the poster […]
Identify functional chimeric antigen receptors three months faster with Alloy’s end-to-end CAR discovery
Webinar overview: Looking for a way to accelerate your CAR-T therapeutic development projects? This presentation highlights how Alloy’s comprehensive platform and expertise can enable you to: Streamline end-to-end CAR discovery: Learn how Alloy’s full stack technologies enable discovery and screening of functional CARs with unprecedented speed and cost efficiency, overcoming limitations of conventional two-step processes. […]
Leveraging Human Lambda Light Chains in Antibody Discovery
Harnessing the potential of human lambda light chains in antibody discovery Download White Paper Contact Us Expanding antibody discovery potential with human lambda light chains Despite the kappa/lambda ratio in human circulation being between 1.5 and 2, therapeutic antibodies remain heavily biased toward kappa light chain usage. Our white paper explores how Alloy’s ATX-GL platform […]
Discover TCR mimic antibodies that Target Previously “Undruggable” Intracellular Proteins with Keyway™ TCR
Webinar Overview: Unlock access to intracellular protein targets and maximize TCRm/TCR-based therapeutic antibody discovery with this presentation by Dr. Dongxing Zha that reveals how Alloy’s proprietary Keyway™ TCRm Discovery Platform and expertise can: Overcome challenges to intracellular protein-targeted drug discovery: Learn how the Keyway™ TCRm Discovery Platform identifies TCR mimic (TCRm) antibodies that target intracellular […]